Author:
Worbe Noémie,Damian Louise,Le Cam-Duchez Véronique,Levesque Hervé,Michel Pierre,Quak Elske
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference14 articles.
1. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors;Strosberg;N Engl J Med,2017
2. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course;Bergsma;Eur J Nucl Med Mol Imaging,2016
3. Therapy-related hematological malignancies after peptide receptor radionuclide therapy with 177Lu-DOTA-Octreotate: incidence, course & predicting factors in patients with GEP-NETs;Bergsma;J Nucl Med,2017
4. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with Gastroenteropancreatic and Bronchial neuroendocrine tumors;Brabander;Clin Cancer Res,2017
5. Prospective validation of the International society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation;Bakhtiari;Crit Care Med,2004
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献